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Background: Sarcoidosis is a systemic granulomatous disease of unknown cause that affects
the lungs in over 90% of cases. Breath analysis by electronic nose technology provides exhaled
molecular profiles that have potential in the diagnosis of several respiratory diseases.
Objectives: We hypothesized that exhaled molecular profiling may distinguish well-
characterized patients with sarcoidosis from controls. To that end we performed electronic
nose measurements in untreated and treated sarcoidosis patients and in healthy controls.
Methods: 31 sarcoidosis patients (11 patients with untreated pulmonary sarcoidosis [age:
48.4  9.0], 20 patients with treated pulmonary sarcoidosis [age: 49.7  7.9]) and 25 healthy
controls (age: 39.6  14.1) participated in a cross-sectional study. Exhaled breath was
collected twice using a Tedlar bag by a standardized method. Both bags were then sampled
by an electronic nose (Cyranose C320), resulting in duplicate data. Statistical analysis on
sensor responses was performed off-line by principal components (PC) analyses, discriminant
analysis and ROC curves.
Results: Breathprints from patients with untreated pulmonary sarcoidosis were discriminated
from healthy controls (CVA: 83.3%; AUC 0.825). Repeated measurements confirmed those re-
sults. Patients with untreated and treated sarcoidosis could be less well discriminated (CVA
74.2%), whereas the treated sarcoidosis group was undistinguishable from controls (CVA 66.7%)t of Respiratory Diseases, University of Bari, Piazza Giulio Cesare 11, 70100 Bari, Italy. Tel.: þ39
il.com (S. Dragonieri).
3 Elsevier Ltd. All rights reserved.
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1074 S. Dragonieri et al.Conclusion: Untreated patients with active sarcoidosis can be discriminated from healthy con-
trols. This suggests that exhaled breath analysis has potential for diagnosis and/or monitoring
of sarcoidosis.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a systemic granulomatous disease of un-
known etiology, which commonly affects young and
middle-aged adults throughout the world.1 The estimated
life-time risk varies between 1 and 2% in different ethnic
groups.2 Pulmonary involvement occurs in over 90% of
cases.3 Due to its wide variety in clinical presentation and
subsequent disease course, the diagnosis of sarcoidosis is
challenging and often requires invasive approaches such as
bronchoscopy.1 As a consequence, decisions on whether or
not starting treatment often have to be taken on arbitrary
grounds. Therefore, It would be desirable to have new
diagnostic methods in sarcoidosis that are simple, quick,
non-invasive, cost-effective and with high selectivity. In
the past years, several serum markers have been associ-
ated with the presence of sarcoidosis, including
angiotensin-converting enzyme, neopterin and soluble IL-2
receptor, but none of them showed an adequate sensi-
tivity to be useful for screening for the diagnosis of
sarcoidosis.4
During the past few years, the analysis of exhaled
breath has been proposed as a novel diagnostic tool for a
variety of lung diseases.5 It is well known that exhaled
breath contains thousands of volatile organic compounds
(VOCs) deriving from various metabolic and inflammatory
pathways in the body.6,7 These can be measured by tech-
niques like gas chromatographyemass spectrometry
(GCeMS), Time of Flight Mass Spectrometry (TOF-MS) and
Ion-Mobility spectrometry (IMS), which are the gold-
standard for VOCs analysis. A feasibility study by Westh-
off et al. showed characteristic peaks of volatile organic
compounds in exhaled air of patients with sarcoidosis by
using IMS.8
However, these procedures are arduous and expensive,
which has limited their clinical applicability.
Electronic noses represent an innovative method of
VOCs sampling, because these devices can identify a
mixture of VOCs translating it into a breath profile
(breathprint).9 Differently from GCeMS, they allow a
relatively inexpensive, on-site and instantaneous distinc-
tion of breathprints by pattern recognition, without iden-
tification of the individual molecular components.10
Notably, several proof of concept studies have shown that
exhaled breath molecular profiling by electronic noses
could be useful in the medical diagnostics,5 in particular in
the diagnosis of several respiratory diseases such as lung
cancer11e13 asthma,14,15 COPD15 and pleural malignant
mesothelioma.16
Based on the above, we hypothesized that the exhaled
breath molecular profiling by an electronic nose can
correctly discriminate patients with pulmonary sarcoidosis
from controls with adequate repeatability.Methods
Patients
A total number of 56 patients volunteered to participate to
this study. All individuals were never-smoking adults (18e75
years). The study population included 3 groups of patients:
patients with untreated pulmonary sarcoidosis, patients
with treated pulmonary sarcoidosis and a healthy control
group. Measurements were performed in May 2011. During
JanuaryeMarch 2011 otherwise unselected patients, how-
ever fulfilling the inclusion criteria, were approached dur-
ing regular visits to the outpatient clinic of the Amsterdam
University Medical Center. Those who volunteered partici-
pated in the study, whilst controls were recruited amongst
personal contacts.
The untreated pulmonary sarcoidosis group was
composed of 11 patients with a more recently established
diagnosis or longer standing stable disease without previous
or current medical treatment. The treated pulmonary
sarcoidosis group consisted of 20 patients with stage 0eIV
pulmonary sarcoidosis currently under inhaled and/or
systemic therapy (corticosteroids alone, corticosteroids
combined with azathioprine, methotrexate or,
hydroxychloroquine). Sarcoidosis was defined as presence of
histological evidence of non-caseating granulomas in pa-
tients with bilateral hilar adenopathy on the chest roent-
genogram, except for those with particular conditions where
a diagnosiswas based on clinical-radiographic findings alone,
such as Lo¨fgren syndrome, Heerfordt syndrome, bilateral
hilar gallium-67 uptake and positive PETscan.1 Patientswere
radiologically staged using currently accepted consensus
criteria.1 Patients with clinically established conditions
affecting the exhaled VOCs spectrum were not eligible for
participation, in particular Diabetes Mellitus, respiratory
disease other than sarcoidosis, autoimmune disease, renal
dysfunction, cardiac failure, prior or current malignancies
and respiratory tract infections requiring antibiotics and/or
oral steroids in the 4 weeks preceding the study.
The control group was composed by 25 subjects with a
negative history of chest symptoms and without of any
known disease.
The study was approved by the Amsterdam University
Medical Centre Ethics Committee and all patients gave
their written informed consent.
Study design
The study had a cross-sectional case-control design. The
measurements were performed at one visit. Patients were
asked to refrain from eating and drinking at least for
3 h before the study. Exhaled breath was collected in
duplicate and sampled by the electronic nose.
Table 1 Clinical characteristics of the study population.
Untreated
sarcoidosis
Treated
sarcoidosis
Healthy
controls
Patients (n) 11 20 25
Age
(yrs, mean  SD)*
48.4  9.0 49.7  7.9 39.6  14.1
Males 4 13 11
Females 7 7 14
FVC %pred 87.8  11.2 88.5  16.3 n.d.
DLCO %pred 68.2  12.4 62.9  13.3 n.d.
Serum ACEU (u/mg) 111.6  58.5 72.6  37.4 n.d.
Radiostage
0/1/2/3/4
1/2/5/2/1 2/2/2/1/13 n.d.
Time since diagnosis
(yrs, mean  SD)
6.8  5.5 11.1  6.5
Treatment**:
C/C þ A/M/H
n.d. 12/4/1/3
* Z p < 0.05 untreated p.s. vs. controls; p < 0.01 treated vs.
controls.
U Z p < 0.05 by independent samples t-test.
**C: corticosteroids; C þ A: corticosteroids and azathioprine; M:
methotrexate; H: hydroxychloroquine.
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Exhaled breath analysis was performed as previously
described.14 In short, patients breathed tidally for
5 min through a 3-way non-rebreathing valve connected to
an inspiratory VOC-filter (A2, North Safety, NL). Afterward,
patients exhaled a single vital capacity volume into a Tedlar
bag, connected to the electronic nose. The entire maneu-
ver was repeated after 5 min resting, which provided
duplicate samples.
Electronic nose
We used a commercially available handheld electronic
nose, (Cyranose 320, Smith Detections, Pasadena, CA, USA)
with a nano-composite array of 32 organic polymer sensors.
When the sensors are exposed to a mixture of VOCs the
polymers swell, inducing a change in their electrical resis-
tance.10 The raw data are captured as the changes in
resistance of each of the 32 sensors in an onboard data-
base, thereby producing a distribution (breathprint) that
describes the VOC mixture and that can be used for
pattern-recognition algorithms.9
Data analysis
Raw data were analyzed by SPSS software version 16.0
(SPSS Inc., Chicago, IL, USA), using analysis strategies that
purposely limit false-discoveries.17 Data were reduced to a
set of principal components capturing the largest amount of
variance of the original 32 sensors. Univariate ANOVA
analysis was used to select the principal components that
best discriminated among groups. Afterward, these prin-
cipal components were used to perform a linear Canonical
Discriminant Analysis (CDA), to classify cases into a cate-
gorical partition. We used the “leave-one-out method” to
calculate the Cross Validated Accuracy percentage (CVA,
%). The CVA provides a percentage that estimates how
accurately a predictive model will perform in practice. For
each case the probability of a positive diagnosis was
calculated on basis of the canonical discriminant function.
These probabilities were subsequently used to create a
receiver operator curve (ROC-curve) with 95% confidence
limits. The sample size calculation was based on estimating
the standard error (SE) of the percentage correctly classi-
fied patients. The reliability of the percentage correct
classification C is dependent on SE, whilst SE itself is a
function of p: SE Z O[C(100  C )/n]. If C is between 85%
and 100% the current sample sizes per subgroup (11, 20 and
25 patients, respectively) provide SE values between 7 and
9%. A p-value of <0.05 was considered significant.
Results
The patient characteristics of the three groups are
described in Table 1. Patients with untreated and treated
sarcoidosis were slightly older than controls (p < 0.05 and
p < 0.01, respectively). Serum ACE was higher in untreated
patients with sarcoidosis compared to those treated
(p < 0.01).The radiological stages of patients with sarcoidosis are
also shown in Table 1. Eight out of eleven untreated pa-
tients had hilar and mediastinal lymphadenopathy and/or
pulmonary infiltrates without signs of lung fibrosis (stage
1e3), whereas fourteen out of twenty treated patients had
advanced disease with reticular opacities and evidence of
pulmonary fibrosis (stage 4).
The two-dimensional PCA plot showed that patients with
untreated sarcoidosis could be distinguished from healthy
controls (Fig. 1). Canonical discriminant analysis was then
performed on the data and showed a CVA% of 83.3
(p < 0.001). The area under the curve of the ROC-curve for
the discrimination between untreated sarcoidosis and
healthy controls was 0.825 (Fig. 2). Analysis of exhaled air
from the second bag reproduced these results (untreated
sarcoidosis vs. controls: CVA% 86.1, p < 0.001, AUC 0.853).
However, breathprints of untreated sarcoidosis patients
were barely separated from those of the treated sarcoidosis
group, with cross-validated accuracy of 74.2%. Analysis of
the second collected bag confirmed these findings (un-
treated sarcoidosis vs. treated sarcoidosis: CVA% 71.1).
Finally, the comparison between breathprints of treated
patients with healthy controls did not reach statistical
significance for both duplicate measurements (CVA% 66.7
and 64.4, respectively).Discussion
Our study shows that an electronic nose can discriminate
the exhaled breath of patients with untreated sarcoidosis
from healthy controls. The electronic nose could less
adequately distinguish patients with untreated sarcoidosis
from those with treated sarcoidosis. These distinctions
were confirmed when analyzing exhaled air from repeated
samples. However, the electronic nose could not discrimi-
nate treated sarcoidosis from healthy controls. These
Figure 1 Two-dimensional principal component analysis with
2 composite factors showing the discrimination of breathprints
between patients with untreated sarcoidosis (blue circles) and
controls (red triangles). (For interpretation of the references
to color in this figure legend, the reader is referred to the web
version of this article.)
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breath differs between untreated pulmonary sarcoidosis as
compared and controls, warranting further diagnostic vali-
dation of electronic noses in sarcoidosis.
To the best of our knowledge this is the first study using
exhaled breath molecular pattern recognition by electronic
noses in the field of sarcoidosis. Notably, we observed an
adequate separation between the untreated sarcoidosisFigure 2 ROC-curve with 95% confidence interval for diag-
nosis of untreated sarcoidosis compared to controls. AUC was
0.825.group and healthy controls. This was confirmed when using
duplicate measurements. To date, in clinical research the
potential of electronic nose technology has already been
tested for detecting a variety of other diseases, such as
bacterial vaginitis, venous leg ulcer infections, sinusitis,
cerebrospinal fluid leak, urinary tract infections, diabetes
mellitus and renal dysfunction.5,9 The application of elec-
tronic noses in respiratory medicine showed its potential in
diagnosing, phenotyping and monitoring obstructive dis-
eases like bronchial asthma and chronic obstructive pul-
monary disease (COPD). Several studies demonstrated that
patients with asthma could be discriminated from healthy
controls.14,15,18,19 Interestingly, patients with COPD were
also discriminated from asthmatics.15,18 Moreover, a num-
ber of studies with different electronic nose technologies
suggest that exhaled breath profiling may be applicable in
the diagnosis of lung cancer,11e13,20,21 as well as in pleural
malignant mesothelioma.16,22 Finally, several groups have
undertaken efforts to detect Mycobacterium tuberculosis8
and ventilator-associated pneumonia.23,24 The present
findings suggest that the detection of pulmonary sarcoidosis
by electronic nose may also be accomplished.
We paid particular attention in considering methodo-
logical issues such as the selection of groups. All the pa-
tients were carefully selected by generally accepted
consensus criteria.1 This discrimination of a priori diag-
nosed gold-standard groups is essential as first step in the
validation of novel tests according to current guide-
lines.25e27 In addition, we used previously validated sam-
pling techniques and breathing maneuvers14 to minimize
any influence on the exhaled VOC-profile by environmental
VOCs, humidity, expiratory flow-rate or contaminated ma-
terial. We excluded smokers and ex-smokers because to-
bacco smoking is known to change the level of several VOCs
in exhaled breath.28 Moreover, we ruled out patients with
any comorbidities, such as diabetes mellitus, renal failure
and heart disease which have been shown to interfere with
the VOCs spectrum.9,29
Nevertheless, several limitations of our study need to be
acknowledged. First, patients with sarcoidosis were older
than controls, thus potentially introducing an age-bias in
the discrimination of groups. We previously showed that
exhaled breath from young and older patients was not
distinguishable by an electronic nose.14 However, we
cannot exclude that age-related factors have affected our
results. Second, we divided patients with sarcoidosis into
two groups according to their medication usage. Exhaled
breath of the treated sarcoidosis group was not clearly
discriminated from that of untreated patients and controls.
The treatment of our patients with sarcoidosis included
inhaled and/or systemic corticosteroids and other immu-
nosuppressants such as azathioprine and methotrexate.
These medications may affect the VOC-pattern by locally
and systemically modifying inflammatory and metabolic
pathways, potentially leading to the poor discrimination
between treated sarcoidosis patients and controls.
Nevertheless, we did not observe a sharp discrimination
between treated and untreated sarcoidosis, suggesting that
medication usage may not be a key element in the lack of
differentiation between these groups. Not unexpectedly,
there were many more patients with advanced disease
(stage 4) in treated group. Therefore, our data raise the
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between early stage granulomatous inflammation and
control conditions, whereas it cannot distinguish late stage
fibrotic inflammation or (partly) medically suppressed
inflammation from control.
Third, even though we had 56 patients in the study, the
current sample size was relatively limited. Nevertheless, it
appeared to be sufficient for obtaining a well-defined
separation between breathprints of untreated sarcoidosis
and controls. This is unlikely to be explained by accident or
error, since repeated sampling confirmed our findings. The
95% confidence limits of the ROC-curve are in line with this.
Undoubtedly, further investigations with a larger and in-
dependent population are required for testing exhaled
breath profiling in various stages of sarcoidosis.
Fourth, we did not include a control group of patients
with chest diseases having a similar clinico-radiological
presentation, such as tuberculosis, hypersensitivity pneu-
monitis, fibrotic lung diseases or even Beryllium disease,
which is notably difficult to distinguish from sarcoidosis.
This is mandatory for the next step in the validation of
electronic noses as diagnostic tools for sarcoidosis.
How can we interpret our results? It appears that the
exhaled breath of patients with untreated pulmonary
sarcoidosis is different from that of healthy controls.
Sarcoidosis is characterized by a non-caseating granulo-
matous inflammation, caused by an unknown “sarcoid”
antigen which leads to an amplified Th-1 like lymphocytic
response and to the release of a variety of cytokines and
chemokines, including pro-fibrotic factors, pro-
inflammatory agents and macrophage-derived sub-
stances.30 It is likely that these inflammatory processes may
change several metabolic pathways, thereby providing
different VOCs in the exhaled air. There are only few data
about exhaled breath analysis in sarcoidosis. Interestingly,
elevated levels of H2O2 and 8-isoprostane (markers of
oxidative stress) and ethane (marker of lipid oxygenation)
were detected in the exhaled breath condensate of pa-
tients with sarcoidosis.30 It is essential to emphasize that
electronic noses do not identify which specific VOCs are
responsible for the distinctive patterns between sarcoidosis
and controls. This requires GCeMS analysis, which needs to
be applied in follow-up studies, when aiming to identify the
molecular pathways that are driving the currently observed
discrimination. Such studies can also be helpful in the
development of specific sensors tailored for a given dis-
ease, as has already been done for lung cancer.12
What are the clinical implications of our findings? Using
an electronic nose, it appears to be feasible to distinguish
exhaled breath from patients with untreated pulmonary
sarcoidosis from healthy subjects. Diagnostic potential
based on probabilistic assessment is highly valuable in
medicine, provided that the sensitivity and specificity of
the eNose meets the demands for the confirmation and/or
the exclusion of the disease.25 Our data warrant external
validation studies in larger cohorts which will better enable
the comparison of breathprints across radiographic stages.
This needs to be compared with other granulomatous dis-
eases, as previously mentioned. If successful, electronic
noses may have the potential to become a relatively inex-
pensive, easy to use and non-invasive diagnostic tool for
sarcoidosis. They may either qualify as screening devices(with maximal sensitivity) aimed to exclude sarcoidosis
amongst patients with suspected sarcoidosis, or as diag-
nostic instrument for selecting patients for further, more
specific diagnostic procedures.
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